Advertisement
The New Frontiers in Individualized Breast Cancer Therapy symposium, animportant continuing medical education event at the SABCS, will take place onSaturday, December 13, from 7:30-10 pm, at the Grand Hyatt, San Antonio.Additionally, a mini-symposium and a series of poster presentations willhighlight results from studies analyzing Agendia's MammaPrint(R), aFDA-cleared test that identifies the risk of breast cancer recurrence andprovides doctors with the rationale to assess the benefits of chemotherapy.
Advertisement
Full study results will be discussed at a mini-symposium and thefollowing embargoed poster sessions and discussions:
New Frontiers in Individualized Breast Cancer Therapy
The New Frontiers in Individualized Breast Cancer Therapy symposiumupdates physicians on the latest information regarding the development ofmolecular diagnostic assays for breast cancer and how to integrate thisinformation into their everyday practices. The technology behind multigeneexpression profiling assays will be discussed, includingimmunohistochemistry, RT-PCR, and DNA microarray-based assays. The use ofmicroarray technology in breast cancer sub-typing will also be covered aswell as key clinical data from prospective validation studies establishingthese assays as prognostic and/or predictive in patients with node-negativeearly-stage breast cancer. Comparisons of molecular profiling assays totraditional clinicopathologic criteria and online algorithms will bereviewed, and the utility of these assays in patients with node-positivedisease and ongoing clinical trials of multigene assays in breast cancer willbe discussed. For more information please go toNewFrontiers.CancerLearning.com.
The faculty will consist of:
William F. Symmans, MD, Assistant Professor of Pathology, The Universityof Texas M. D. Anderson Cancer Center, Houston, TX
Kelly K. Hunt, MD, F.A.C.S, Professor of Surgery, Department of SurgicalOncology, Chief Surgical Breast Section, The University of Texas M. D.Anderson Cancer Center, Houston, TX; Chair Breast Committee, American Collegeof Surgeons Oncology Group
Rowan T. Chlebowski, MD, PhD, Professor of Medicine, UCLA School ofMedicine, Chief of Medical Oncology at Harbor-UCLA Medical Center, Torrance,CA.
Emiel J Rutgers, MD, PhD, Professor of Surgery, Department of SurgicalOncology, Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital,Amsterdam, the Netherlands
About MammaPrint(R)
MammaPrint is the first 'in vitro diagnostic multivariate index assay'(IVDMIA) cleared by the U.S. Food and Drug Administration (FDA). FDAclearance requires clinical and analytical validation and reporting systemsto ensure patient safety issues are addressed. Highly accurate, MammaPrintidentifies patients with early metastasis - those patients who are likely todevelop metastases within five years following surgery. Several authoritativestudies have shown that chemotherapy particularly reduces early metastasisrisk. In planning treatment, the MammaPrint test result provides a doctorwith a clear rationale to assess the benefit of adjuvant chemotherapy inaddition to other clinical information and pathology tests.
All MammaPrint tests are conducted in Agendia's CLIA-certified servicelaboratory. All other breast cancer recurrence assays currently marketed havenot been subject to the rigorous FDA clearance process.
About Agendia
Agendia is at the forefront of the personalized medicine revolution,striving to bring more effective, individualized treatments within reach ofpatients. Building on a cutting edge genomics platform for tumor geneexpression profiling, the company's tests aim to help physicians moreaccurately tailor cancer treatments. The company markets four products withseveral new genomic tests under development. In addition, Agendiacollaborates with pharmaceutical companies to develop highly effectivepersonalized drugs in the area of oncology. Agendia is based in HuntingtonBeach, California, and in Amsterdam, The Netherlands. For more informationplease visit http://www.agendia.com.Thursday, 12/11/08, 5:30pm - 7:30pm #1063, Poster Session 1: Prognostic Factors and Biomarkers - Clinical Testing and Validation, "The 70-gene prognosis profile predicts early metastases in postmenopausal breast cancer patients." Presenter: Stella Mook, MD, Netherlands Cancer Institute. Thursday, 12/11/08, 5:30pm - 7:30pm CST #1084, Poster Session 1: Prognostic Factors and Biomarkers - Clinical Testing and Validation, "Benefit of the 70-gene profile for widely used guidelines: an answer to increased selection for adjuvant chemotherapy in breast cancer." Presenter: Michael Knauer, M.D., Netherlands Cancer Institute. Friday, 12/12/08, 2pm - 3:30pm CST Mini-symposium 2, Molecular Profiling for Guiding Therapeutic Decisions: "RNA". Presenter: Laura Van 't Veer, PhD, Netherlands Cancer Institute. Friday, 12/12/08, 5pm - 7pm CST #305 Poster Discussion 3: Circulating Tumor Cells and Marrow Micrometastases, "A multi-marker QPCR panel for the detection of circulating tumor cells predicts survival in breast cancer patients." Presenter: Laura Van 't Veer, PhD, Netherlands Cancer Institute. Friday, 12/12/08, 5pm - 7pm CST #3007, Poster Session 3: Detection/Diagnosis - Diagnostic Pathology, "Microarray-based determination of ER, PR and HER2 receptor status: validation and comparison with IHC assessments." Presenter: Paul Roepman, PhD, Agendia. Saturday, 12/13/08, 7am - 9am CST #4171, Poster Session 4: Late Acceptances, "Identification of a low risk subgroup in Her2-positive breast cancer by the 70-gene prognosis signature." Presenter: Michael Knauer, MD, Netherlands Cancer Institute Sunday, 12/14/08, 7am - 9am #6034, Poster Session 6: Prognosis and Response Predictions - Biomarkers and Other Factors, "Biology of Breast Cancers that Are Screen Detected vs. Locally Advanced or Young Age Should Inform How We Approach Early Detection and Prevention." Presenter: Laura Esserman, MD, UCSF Carol Franc Buck Breast Care Center.
SOURCE Agendia BV
